Royalty Pharma Stock Price

RPRX Community Fair Values

• AN

  

  AnalystConsensusTarget

  Consensus Narrative from 8 Analysts

  Integration Will Generate Over $100 Million In Savings By 2026

  Key Takeaways The integration of Royalty Pharma's external manager will boost net margins through significant cost savings and eliminate management fees, enhancing shareholder value. Royalty Pharma's growing pipeline of new therapies and synthetic royalties could significantly drive future revenue growth and earnings, indicating strong market opportunities.

  US$42.15

  FV

  10.1% undervalued intrinsic discount

  18.27%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  20users have followed this narrative

  6 days ago author updated this narrative
• AN

  

  AnalystLowTarget

  Consensus Narrative from 8 Analysts

  Patent Cliffs And Regulatory Challenges Will Limit Future Returns

  Key Takeaways Global drug pricing reforms, faster generic approvals, and greater regulatory scrutiny threaten the longevity and value of Royalty Pharma’s royalty streams and earnings stability. Rising interest rates and increased competition for royalty assets are compressing margins, elevating acquisition costs, and reducing the company’s financial flexibility and equity appeal.

  US$32.19

  FV

  17.8% overvalued intrinsic discount

  14.05%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  6 days ago author updated this narrative
• AN

  

  AnalystHighTarget

  Consensus Narrative from 8 Analysts

  Internalization And Acquisition Will Drive Future Efficiency Gains

  Key Takeaways Internalization of management and acquisition strategies are expected to enhance financial performance and operational alignment, leading to improved margins and efficiency. Expansion through synthetic royalties and strategic share repurchases demonstrates focus on new revenue streams and maximizing shareholder value.

  US$54.00

  FV

  29.8% undervalued intrinsic discount

  23.23%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  13 days ago author updated this narrative